The application is based on results from the Phase 3 Vivacity-MG3 trial, which demonstrated that nipocalimab, in combination with standard of care, significantly improved outcomes in patients with seropositive generalized myasthenia gravis.
Johnson & Johnson Submits Biologics License Application for Nipocalimab for Patients with Seropositive Generalized Myasthenia Gravis
Leave a comment
